Kenvue posts higher Q2 profit, sales as Kimberly-Clark deal nears

Kenvue reported higher Q2 profit and sales on increased prices and volumes, as its turnaround continues ahead of the Kimberly-Clark acquisition.

The results follow Kimberly-Clark's Q2 10-Q filing on Aug. 4, which confirmed the Kenvue acquisition remains on track for H2 2026. Kimberly-Clark also completed its Professional segment divestiture during the quarter.

Kenvue's growth was driven by higher prices and volumes across its consumer health portfolio, which includes brands such as Tylenol, Neutrogena, and Listerine. The company has been executing a turnaround strategy focused on brand investment and operational efficiency since its 2023 spinoff from Johnson & Johnson. Specific revenue and earnings per share figures were not disclosed in the preliminary release.

Kimberly-Clark reported modest sales growth and strong margin expansion in Q2, supported by productivity gains and transformation initiatives, though it faced headwinds from China and input costs. The company's Q2 results were also offset by higher tax expense and discontinued operations related to the IFP divestiture.

The improved earnings performance could support Kenvue's valuation as Kimberly-Clark prepares to close the acquisition in H2 2026. The deal would combine Kimberly-Clark's personal care business with Kenvue's consumer health portfolio, creating a major player in the global consumer products sector.

Kenvue has been streamlining its operations and investing in its core brands as part of the turnaround effort. The company's focus on pricing discipline and volume growth has helped offset broader industry pressures from input cost inflation and supply chain disruptions. The consumer health sector has faced persistent cost pressures, with competitors such as Procter & Gamble also navigating higher raw material expenses across their portfolios.

The acquisition is expected to close in H2 2026. Investors will be watching for further details on the deal timeline and integration plans in upcoming earnings calls. Kimberly-Clark's completion of the IFP divestiture simplifies its portfolio ahead of the Kenvue integration, allowing management to focus on the combined entity's growth strategy.

The combined company would bring together Kimberly-Clark's tissue and personal care franchises with Kenvue's over-the-counter medicine and self-care brands, creating a diversified consumer products giant competing directly with Procter & Gamble and Unilever across multiple categories. The deal is expected to generate significant cost synergies through combined supply chains, distribution networks, and marketing operations.

The stronger Kenvue results provide a positive backdrop for the pending acquisition, potentially supporting the deal's valuation. The next event to watch is the expected H2 2026 closing, with regulatory approvals and integration planning as key items to monitor.

This article is for informational purposes only and does not constitute investment advice.